For research use only. We do not sell to patients.
Ionizable lipids / LP-01
LP-01 chemical structure
Product imageResearch use only
CAT. NO. DC31000Featured

LP-01

Pack size & price

USD
TotalUS$300
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

LP-01 is a biodegradable ionizable lipid used in the LNP-INT01 delivery system for Cas9 mRNA and guide RNA. Published rodent studies show liver-directed genome editing, sustained reduction of serum transthyretin and rapid clearance of the lipid and RNA components.

Open full Formulation & Performance →

Literature evidence · DC31000

Formulation & Performance

The 2018 Cell Reports paper reports durable Ttr editing after transient exposure to LP-01-containing LNPs. Serum protein reduction, whole-liver DNA editing and lipid clearance are reported separately.

The paper names the lipid LP01 and the complete formulation LNP-INT01. DC31000 is the lipid component, not a preformulated editor product.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
LP-01DC31000852.292450.383531
DSPCDC57005790.1590.071113
CholesterolDCD-041386.65440.170126
DMG-PEG2000DC40169250720.050140

Experimental Procedures, LNP Formulation: LP01 / DSPC / cholesterol / PEG2k-DMG = 45:9:44:2 mol%. Reported N/P = 4.5; mRNA:sgRNA = 1:1 by mass. These are different quantities. DMG-PEG2000 uses MW 2507 for the calculated component masses.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
LP-01——
DSPC——
Cholesterol——
DMG-PEG2000——

Formulation and physical properties

Study / parameterReported evidenceSource / interpretation
Composition45% LP01, 9% DSPC, 44% cholesterol, 2% PEG2k-DMGMain-text Experimental Procedures
Charge/cargo ratiosN/P 4.5; Cas9 mRNA:sgRNA 1:1 mass ratioN/P is amine-to-RNA-phosphate, not lipid:RNA mass ratio
Particle size and RNA associationMain text reports formulations <100 nm and >95% encapsulationThe underlying SI Table S1 was not independently retrieved; no narrower values assigned
IonizationApproximate pKa 6.1 reported for LP01Results section; assay context should accompany comparisons

Cellular delivery and in vitro/in vivo relationship

Study / parameterReported evidenceSource / interpretation
Cell modelMouse primary hepatocytes; transfection assessed at 42–48 h by sequencingExperimental Procedures, LNP Delivery In Vitro
Guide screeningIn vitro guide activity correlated with the corresponding mouse-liver screenMain Fig. 1c; guide selection affects the delivered system
Co-deliveryMain text reports coformulation more effective than split deliverySI Fig. S1 referred to by the main text; individual SI panels not rechecked
InterpretationResults depend on lipid, formulation and RNA design togetherThe activity is not an intrinsic potency value of the pure lipid

Mouse liver editing and durability

Study / parameterReported evidenceSource / interpretation
Long-term studyCD-1 mice; single systemic dose 0.3, 1 or 3 mg/kg RNA; followed up to 12 monthsMain Fig. 2f–h; n = 5 at indicated collection points
Highest-dose resultAt 3 mg/kg, >97% serum TTR reduction and approximately 70% whole-liver DNA editingMain Results and Fig. 2; protein knockdown is not editing percentage
DurabilityEditing and protein reduction remained stable through the reported 12-month follow-upNot persistence of intact LNP or Cas9 mRNA
Repeated administrationMultiple doses produced cumulative editing in the reported studyMain Fig. 3; do not substitute a multi-dose result for the single-dose result

Rat response and component clearance

Study / parameterReported evidenceSource / interpretation
Rat efficacySystemic 1, 2 or 5 mg/kg; dose-dependent response with approximately 70% liver editing and >90% TTR reduction at high responseMain Fig. 4; outcomes depend on guide and dose
RNA clearanceCas9 mRNA and guide RNA were undetectable in plasma/liver by 72 h in the reported assayMain Fig. 2a–b; assay detection limit applies
Lipid turnoverReported LP01 liver half-life approximately 6 hMain Fig. 2c
Editing kineticsEditing reached its maximum later, around 96 hMain Fig. 2d–e; pharmacokinetics and pharmacodynamics are separate

Tolerability and scope

Study / parameterReported evidenceSource / interpretation
Reported endpointsMain text describes mouse/rat tolerability with respect to cytokine responses and body-weight changeDetailed supporting panels S2c–h were not independently rechecked
Tissue selectivityLiver was the principal delivery site, with low detectable editing also reported in spleen and kidneyMain Discussion and Fig. 4c; liver-directed does not mean exclusive
Study boundaryRodent preclinical evidence; no human efficacy or universal safety claimSpecific cargo, dose and assay conditions matter
Open itemsComplete original SI and panel-level formulation characterization remain to be verifiedDo not infer exact PDI, NOAEL or shelf life

Original study figures

Original Figs. 1–4: cellular/liver activity, durability, repeat dosing and rat results — Original source figures.

References and source locations

  1. Finn JD, Smith AR, Patel MC et al. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Reports 22, 2227–2235 (2018). DOI: 10.1016/j.celrep.2018.02.014.
CAS No.1799316-64-5
Chemical NameLP-01
Synonyms3-[4,4-Bis(octyloxy)-1-oxobutoxy]-2-[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]propyl (9Z,12Z)-9,12-octadecadienoate;CIN16645;[2-[3-(diethylamino)propoxycarbonyloxymethyl]-3-(4,4-dioctoxybutanoyloxy)propyl] (9Z,12Z)-octadeca-9;(9Z,12Z)-3-((4,4-Bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate;LP01， LP 01
SMILESO(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])(C([H])([H])C([H])([H])C(=O)OC([H])([H])C([H])(C([H])([H])OC(=O)OC([H])([H])C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
FormulaC50H93NO9
M.Wt852.292
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Finn JD, Smith AR, Patel MC et al. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Reports 22, 2227–2235 (2018). DOI: 10.1016/j.celrep.2018.02.014.
F&PFormulation & PerformanceComposition, study results and referencesRead online →
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg11.7331 mL2.3466 mL1.1733 mL
25 mg29.3327 mL5.8665 mL2.9333 mL
50 mg58.6653 mL11.7331 mL5.8665 mL
100 mg117.3307 mL23.4661 mL11.7331 mL
250 mg293.3267 mL58.6653 mL29.3327 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.